Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:

• Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00)
• Biology and Current Clinical Management of PNH (36:35)
• Future Directions in PNH Management (55:34)
• Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)

CME information and select publications

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:

• Perspectives on advances in the management of prostate cancer over the last decade (0:00)
• Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39)
• EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25)
• Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20)
• Management of locally advanced prostate cancer with and without biochemical recurrence (23:58)
• PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35)
• CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41)
• Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38)
• Other potential novel therapeutic strategies for prostate cancer (42:28)
• Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57)
• Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49)
• Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)

CME information and select publications

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

• Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
• Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
• Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
• Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
• Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
• Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
• Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
• Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
• Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
• Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
• Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.

• Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00)
• Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly (31:46)

CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.

• Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00)
• HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17)

CME information and select publications

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics.

• Introduction (0:00)
• Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30)
• Biliary Tract Cancers (BTCs) — Dr Finn (33:16)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics.

• Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00)
• Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42)

CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics.

• Introduction (0:00)
• Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates in Multiple Myeloma (MM) — Dr Callander (8:25)
• Integration of Other Novel Therapies into the Management of Newly Diagnosed and Relapsed/Refractory MM — Dr Richardson (31:52)

CME information and select publications

Featuring perspectives from Dr Edward B Garon and Dr Corey J Langer, including the following topics.

• Role of Immune Checkpoint Inhibitors in Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (0:00)
• Immune Checkpoint Inhibitors and Other Emerging Therapeutic Approaches for Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon (30:08)

CME information and select publications

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Henela Yu, including the following topics.

• Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Yu (0:00)
• Care of Individuals with Other Targetable Genomic Abnormalities — Dr Dagogo-Jack (31:01)

CME information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Rana R McKay, including the following topics.

• Role of Hormonal Therapy in Prostate Cancer (PC) Management — Dr McKay (0:00)
• Evidence-Based Use of Other Therapeutic Approaches — Dr Antonarakis (35:15)

CME information and select publications